Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ESSA Pharma Inc.

Get SEC filing alerts via email and in your feed for ESSA Pharma Inc.

EPIX

ESSA Pharma Inc.

About ESSA Pharma Inc.

ESSA Pharma Inc. is a clinical-stage biotechnology company focused on developing novel therapies for prostate cancer. Its proprietary small molecule inhibitors target the androgen receptor's N-terminal domain to overcome resistance mechanisms. The company’s lead candidate, masofaniten (EPI-7386), was designed to treat advanced prostate cancer, often in combination with existing antiandrogens. ESSA aims to improve androgen suppression and delay drug resistance in AR-driven prostate cancer.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ESSA Pharma Inc.

1
1
ESSA Pharma Inc. ESSA Pharma Reports $4M Loss for Nine Months Ending June 30, 2025, Amid Strategic Transition

Via official filing (AI summary) | 10 months ago | 0 comments

2
1
ESSA Pharma Inc. ESSA Pharma Reports $6.4 Million Loss, Reviews Strategic Options After Clinical Trial Termination

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
ESSA Pharma Inc. ESSA Pharma Reports $8.5 Million Loss, Ceases Clinical Trials for Masofaniten

Via official filing (AI summary) | over 1 year ago | 0 comments